Clinical Trials

406 enrolled 11 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00658814 2026-03-18

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

133 enrolled 10 charts

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00792948 2026-03-18

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

97 enrolled 7 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT01522976 2026-03-18

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Classical hematologyMyeloidOther hematologic neoplasm

282 enrolled 11 charts

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT01627041 2026-03-18

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

178 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT01841723 2026-03-18

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

44 enrolled

Leukemia, Hairy Cell

NCT02143414 2026-03-18

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

53 enrolled 12 charts

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02392429 2026-03-18

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

87 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT03190915 2026-03-18

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

CNSOther hematologic neoplasm

10 enrolled 11 charts

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03289910 2026-03-18

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

25 enrolled 15 charts

Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04439201 2026-03-18

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

40 enrolled 9 charts

Lymphoma, Hematologic Neoplasms

NCT04439292 2026-03-18

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-03-18

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04904588 2026-03-18

ACCESS

LymphoidMyeloidOther hematologic neoplasmOther neoplasm

300 enrolled

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05600894 2026-03-18

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Classical hematologyMyeloidOther hematologic neoplasm

132 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT06303167 2026-03-18

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05478512 2026-03-17

VIS

78 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03591510 2026-03-13

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

22 enrolled

Leukemia, Myeloid, Acute

NCT04557098 2026-03-12

MajesTEC-1

194 enrolled 1 FDA

Hematologic Neoplasms

NCT04746235 2026-03-12

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

85 enrolled

Leukemia, Myeloid, Acute

NCT05458297 2026-03-12

MK-2140-006

223 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04128501 2026-03-06

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

100 enrolled

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04231851 2026-03-06

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

30 enrolled 15 charts

Leukemia, Myeloid, Acute

NCT05306301 2026-03-06

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

32 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

33 enrolled 16 charts

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

99 enrolled

Leukemia, Myelodysplastic Syndromes

NCT05268003 2026-03-05

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

26 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05768711 2026-03-05

AVENHIR

44 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03849651 2026-03-04

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

69 enrolled 17 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT04214249 2026-03-04

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

49 enrolled 32 charts

Leukemia, Myeloid, Acute

NCT05479994 2026-03-04

Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

100 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03516279 2026-03-02

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

40 enrolled

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT05650723 2026-02-25

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06524375 2026-02-25

BRAVE

118 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06637501 2026-02-23

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

94 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03672539 2026-02-20

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02756897 2026-02-19

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

234 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02210078 2026-02-17

Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection

49 enrolled

Cytomegalovirus Infections, Hematologic Neoplasms

NCT02846623 2026-02-17

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome

50 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02861417 2026-02-17

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

LymphoidMyeloidOther hematologic neoplasmPlasma cell

204 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT03147612 2026-02-17

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

22 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03441061 2026-02-17

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

40 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04761770 2026-02-17

Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

33 enrolled